Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

By D. Michelson, L. Adler, T. Spencer, F. Reimherr, S. West, A. Allen, D. Kelsey, J. Wernicke, A. Dietrich, D. Milton. Biological Psychiatry, 2003

606 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. (2007, methodology): “The ACDS has been used in clinical trials of adult ADHD (Spencer et al, 2001; Michelson et al, 2003).”
Attention-Deficit/Hyperactivity Disorder in Adults (2004, background): “The efficacy, safety, and tolerability have been well-established [41,42].”
Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. (2007, background): “Subsequently, numerous large-scale clinical trials prove the efficacy of these new agents (Biederman et al., 2002; Greenhill et al., 2002, 2005; McCracken et al., 2003; Pelham et al., 1999; Wigal et al., 2005; Wolraich, 2000; Wolraich et al., 2001) and atomoxetine (Michelson et al., 2001, 2003).”
The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. (2006, methodology): “The ACDS has been used in clinical trials of adult ADHD (21,22).”
The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population (2005, methodology): “The second part was the semi-structured clinical interview for recent (past 6 months) DSM-IV adult ADHD that is used in most clinical trials of this disorder (Spencer et al. 1995, 1998, 2001; Michelson et al. 2003).”